Sun Pharma Q1 FY27 Results: US Sales Slip to $427 Million as Generic Business Weighs on Growth
Sun Pharmaceutical Industries reported a 27% year-on-year rise in consolidated net profit for the June quarter, driven by strong growth in its India formulations business and continued momentum in its innovative medicines portfolio. However, despite the healthy profit growth, the pharmaceutical major disappointed investors by missing Street estimates on both revenue and net profit, sending its shares lower in Friday’s trade.
The company’s weaker-than-expected performance in the US generics business overshadowed robust domestic sales and higher-than-expected operating margins.
Get More Updates On : Results Calendar — NSE & BSE
Sun Pharma Q1 FY27 results: Profit rises 27%, revenue grows 10.5%
For the quarter ended June 30, 2026, Sun Pharma reported:
| Metric | Q1 FY27 | YoY Change | Street Expectation |
|---|---|---|---|
| Revenue | ₹15,299.9 Cr | ▲10.5% | ₹15,625 Cr |
| Net Profit | ₹2,894.8 Cr | ▲27% | ₹3,051 Cr |
| Adjusted Net Profit | ₹3,089 Cr | ▲3.1% | — |
| EBITDA | ₹4,417.7 Cr | ▲2.7% | ₹4,255 Cr |
| EBITDA Margin | 28.9% | vs 31.0% LY | 27.2% |
While profit and revenue grew strongly on a year-on-year basis, both headline numbers fell short of analysts’ expectations.
Results miss analyst estimates despite strong EBITDA
Market expectations ahead of the earnings announcement were:
| Metric | Expected | Reported |
|---|---|---|
| Net Profit | ₹3,051 crore | ₹2,894 crore |
| Revenue | ₹15,625 crore | ₹15,299 crore |
| EBITDA | ₹4,255 crore | ₹4,417 crore |
| EBITDA Margin | 27.2% | 28.9% |
Although revenue and profit missed estimates, Sun Pharma outperformed expectations on EBITDA and operating margins, reflecting effective cost management despite pressure in certain international markets.
India business continues to drive growth
The company’s domestic formulations business remained the biggest contributor to growth.
India formulations sales increased 16% year-on-year to ₹5,475 crore, accounting for 36.1% of consolidated revenue.
Sun Pharma also strengthened its leadership position in the domestic pharmaceutical market, with its market share rising to 8.5%, compared with 8.2% a year earlier.
Managing Director Kirti Ganorkar said the company’s performance was supported by strong momentum in India and its innovative medicines portfolio across international markets.
Segment Performance
Strong Areas
- India formulations: ₹5,475 crore (+16% YoY), contributing 36.1% of consolidated revenue.
- Global specialty medicines: US$351 million (+12.8%), accounting for about 22% of total sales.
- EBITDA exceeded analyst expectations despite softer revenue.
Weak Areas
- U.S. formulation sales: US$427 million, down due to weaker generics demand and loss of limited exclusivity for lenalidomide.
- Revenue and PAT both missed consensus estimates.
Research & Development
- R&D spend: ₹826 crore (5.4% of sales)
- Filed 3 ANDAs
- Received approval for 6 ANDAs
Read More : GAIL Q1 FY27 Results Today, July 31, 3:30 PM IST Call: Gas Volumes, Margins in Focus
Innovative medicines remain a bright spot
Sun Pharma’s global innovative medicines business continued its strong growth trajectory.
Sales from innovative medicines increased 12.8% to $351 million, contributing approximately 22% of total revenue.
The company highlighted regulatory approvals for semaglutide products in India, Brazil and South Africa, reinforcing its capabilities in developing complex peptide therapies.
These products are expected to become an increasingly important long-term growth driver.
Organon acquisition remains on track
The reported quarterly profit included an exceptional charge of ₹204 crore, comprising:
- ₹167 crore related to acquisition costs for the proposed Organon transaction.
- ₹37 crore linked to implementation of India’s new labour codes.
Sun Pharma confirmed that Organon shareholders have approved the acquisition, and the transaction remains on track for completion in early 2027, subject to regulatory approvals.
The company expects the deal to close during the fourth quarter of FY27.
Research pipeline remains active
Research and development expenditure stood at ₹826 crore, representing 5.4% of sales during the quarter.
The company:
- Filed three ANDAs
- Received approval for six ANDAs
This steady pipeline continues to support Sun Pharma’s long-term product portfolio expansion.
Shares fall after earnings announcement
Despite reporting higher profits, investor sentiment remained cautious.
Sun Pharma shares were trading around ₹1,972, down nearly 1.5% in afternoon trade after the results announcement.
The market focused on the earnings miss, weaker US sales and declining year-on-year EBITDA margins, despite stronger operating profitability than expected.
Here’s what happened today and why traders reacted
The Sun Pharma Q1 Results delivered a mixed set of numbers.
The company reported healthy double-digit growth in revenue and net profit while beating EBITDA estimates. However, the earnings miss on both revenue and profit, combined with disappointing US sales, overshadowed the positives.
Although India’s formulations business and innovative medicines continued to perform strongly, investors were concerned about slower growth in the US generics business and the impact of the loss of exclusivity for key products.
What Sun Pharma’s Q1 results mean for investors
The Sun Pharma Q1 Results suggest that the company’s long-term growth drivers remain intact, particularly in India’s pharmaceutical market and its global innovative medicines business. The continued expansion of specialty products and progress on the Organon acquisition could strengthen the company’s competitive position over the next few years.
However, near-term challenges remain. Weakness in the US generics business, lower-than-expected revenue and continued pricing pressure could keep investor sentiment cautious. Going forward, the market will closely watch whether Sun Pharma can revive growth in the US while sustaining its leadership in India and expanding its specialty medicines portfolio. If these growth engines continue to deliver, the company could maintain its long-term earnings trajectory despite temporary headwinds.
